vunakizumab 
GtoPdb Ligand ID: 9296
|
Synonyms: AnDajing (Chinese trade name) | SHR-1314
vunakizumab is an approved drug (China NMPA (2024))
Compound class:
Antibody
Comment: Vunakizumab (SHR-1314) is an investigational, humanized monoclonal antibody targeting IL17A, with potential use in autoimmune diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. A patent literature search identifies peptide sequences in WO2015070697, which are identical matches to the heavy and light chain variable regions of vunakizumab (SEQ ID NO 5 and 9 respectively) [2]. These sequences belong to antibody coded Hu049. |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License